Medical Oncology

Internal Medicine

Questions discussed in this category

How do you approach management of a patient with mast cell leukemia?

Do you typically use avapritinib? If you do, what dose do you typically start at?

1 Answer available

What are the most common pain regimens that you use in cancer care?

Can you explain the rationale behind your choices? Are there certain patient factors or logistical barriers which influence your approach?

1 Answer available

For patients with newly diagnosed VTE on IV heparin planned for transition to DOAC, would you start at the loading or maintenance DOAC dose?

If they have been on IV heparin for 3 days, for example, would you subtract those days from the recommended loading dose time?

5 Answers available

What is your preferred frontline treatment for CLL in young patients < 50 years old?

5 Answers available

Given the data from SWOG 1826 suggesting that Nivo-AVD is likely the preferred regimen for advanced Hodgkin lymphoma patients, are there scenarios where alternative regimens may still be preferred?

When now would you consider regimens such as BV-AVD or BrECADD in advanced stage HL?

3 Answers available

Papers discussed in this category

The New England journal of medicine, 2025 Feb 05

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.

Cancers, 2021 Jun 23

Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?

Seminars in hematology, 2023 Dec 26

B-cell receptor immunoglobulin stereotypy in chronic lymphocytic leukemia: Key to understanding disease biology and stratifying patients.

Haematologica, 2020 Nov 01

Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Dec 07

Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.

The New England journal of medicine, 2016-06-30

Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.

Nature medicine, 2021 Dec 06

Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.

Blood advances, 2023 May 09

Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry.

Blood advances, 2026 Jan 28

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-10-20

Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.

The New England journal of medicine, 2024 Oct 17

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.

Related Topics in Medical Oncology